Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D0O6IU
|
||||
| Former ID |
DAP000224
|
||||
| Drug Name |
Phenylephrine
|
||||
| Synonyms |
Cyclomydril; Dilatair; Dionephrine; Doktors; Duration; Fenilefrina; Isophrim; Isophrin; Mesaton; Mesatone; Mesatonum; Metaoxedrin; Metaoxedrine; Metaoxedrinum; Metasympatol; Metasynephrine; Metsatonum; Mezaton; Mydfrin; Neofrin; Neosynephrine; Nostril; Ocugestrin; Phenoptic; Phenylephrinum; Spersaphrine; Visadron; Alcon Efrin; Isopto Frin; Minims Phenylephrine; Nostril Spray Pump; Nostril Spray Pump Mild; Phenylephrine Minims; Prefrin Liquifilm; Relief Eye Drops for Red Eyes; Alconefrin Nasal Drops 12; Alconefrin Nasal Drops 25; Alconefrin Nasal Drops 50; Alconefrin Nasal Spray 25; Ah-Chew; Ak-dilate; Ak-nefrin; Fenilefrina [INN-Spanish]; I-Phrine; L-Phenylephedrine; L-Phenylephrine; M-Methylaminoethanolphenol; M-Oxedrine; M-Sympathol; M-Sympatol; M-Synephrine; Mydfrin (TN); Neo-Synephrine; Neo-Synephrine Nasal Drops; Neo-Synephrine Nasal Jelly; Neo-Synephrine Nasal Spray; Ocu-Phrin Sterile Eye Drops; Phenylephrine (INN); Phenylephrine Minims (TN); Phenylephrine [INN:BAN]; Phenylephrinum [INN-Latin]; R(-)-Phenylephrine; L-(3-Hydroxyphenyl)-N-methylethanolamine; L-1-(m-Hydroxyphenyl)-2-methylaminoethanol; L-m-Hydroxy-alpha-((methylamino)methyl)benzyl alcohol; L-alpha-Hydroxy-beta-methylamino-3-hydroxy-L-ethylbenzene; Tannins, compds. with (R)-3-hydroxy-alpha-((methylamino)methyl)benzenemethanol; Benzenemethanol, 3-hydroxy-alpha-((methylamino)methyl)-, (R)-(9CI); (-)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol; (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine; (R)-3-Hydroxy-alpha-((methylamino)methyl)benzenemethanol; 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Ophthalmic disease [ICD10:H00-H59] | Approved | [1], [2] | ||
| Therapeutic Class |
Ophthalmologicals
|
||||
| Company |
Alcon Canada Inc
|
||||
| Structure |
|
Download2D MOL |
|||
| Formula |
C9H13NO2
|
||||
| InChI |
InChI=1S/C9H13NO2/c1-10-6-9(12)7-3-2-4-8(11)5-7/h2-5,9-12H,6H2,1H3/t9-/m0/s1
|
||||
| InChIKey |
SONNWYBIRXJNDC-VIFPVBQESA-N
|
||||
| CAS Number |
CAS 59-42-7
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
9645, 598369, 3138730, 7980308, 8153766, 11111644, 11335772, 11361011, 11363995, 11366557, 11369119, 11371740, 11374452, 11377281, 11461983, 11485016, 11489096, 11490586, 11492782, 11494915, 11533358, 15147117, 15219459, 29225054, 46506961, 47216760, 47440232, 47588980, 47885392, 48184976, 48334474, 48416424, 49892965, 50100321, 50104255, 50104256, 53787092, 56311763, 56311811, 77849473, 87574602, 90340906, 93166315, 96025051, 103367925, 104310950, 117480201, 124750098, 126524414, 126687263
|
||||
| ChEBI ID |
ChEBI:8093
|
||||
| SuperDrug ATC ID |
C01CA06; R01AA04; R01AB01; R01BA03; S01FB01; S01GA05
|
||||
| SuperDrug CAS ID |
cas=000059427
|
||||
| Target and Pathway | |||||
| Target(s) | D(2) dopamine receptor | Target Info | Agonist | [3], [4] | |
| KEGG Pathway | Rap1 signaling pathway | ||||
| cAMP signaling pathway | |||||
| Neuroactive ligand-receptor interaction | |||||
| Gap junction | |||||
| Dopaminergic synapse | |||||
| Parkinson's disease | |||||
| Cocaine addiction | |||||
| Alcoholism | |||||
| PANTHER Pathway | Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway | ||||
| Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway | |||||
| Dopamine receptor mediated signaling pathway | |||||
| Nicotine pharmacodynamics pathway | |||||
| Reactome | Dopamine receptors | ||||
| G alpha (i) signalling events | |||||
| WikiPathways | Hypothetical Network for Drug Addiction | ||||
| Monoamine GPCRs | |||||
| GPCRs, Class A Rhodopsin-like | |||||
| Genes and (Common) Pathways Underlying Drug Addiction | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| Nicotine Activity on Dopaminergic Neurons | |||||
| References | |||||
| REF 1 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 485). | ||||
| REF 2 | FDA Approved Drug Products from FDA Official Website. 2009. Application Number: (ANDA) 040654. | ||||
| REF 3 | Intracellular Ca2+ and adrenergic responsiveness of cardiac myocytes in streptozotocin-induced diabetes. Clin Exp Pharmacol Physiol. 1999 Apr;26(4):347-53. | ||||
| REF 4 | MMP-2 Induced Vein Relaxation via Inhibition of [Ca(2+)](e)-Dependent Mechanisms of Venous Smooth Muscle Contraction. Role of RGD Peptides. J Surg Res. 2008 Oct 24. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.